TheraRadar
Data updated: May 26, 2026

TONMYA (cyclobenzaprine hydrochloride)

CNS Approved 2025-08-15

Tonmya is a medication used to help adults who have fibromyalgia. It provides a therapeutic option for managing this condition in the adult population. This drug is specifically used for those diagnosed with fibromyalgia to help address their symptoms.

Source: FDA Label • TONIX

How TONMYA Works

While the exact way this drug treats fibromyalgia is not fully understood, it works by interacting with several different receptors in the body, such as serotonin and histamine receptors. It also shares characteristics with tricyclic antidepressants, including the ability to increase norepinephrine levels and produce sedative effects.

Source: FDA Label
1
Indication
--
Phase 3 Trials
0
Years on Market

Details

Status
Prescription
First Approved
2025-08-15
Patent Cliff
2034

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
SUBLINGUAL
Dosage Forms
TABLET

Companies

Active Ingredient: CYCLOBENZAPRINE HYDROCHLORIDE

TONMYA Approval History

2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2025 to 2025
Aug 2025 ORIGINAL
New Form · Type 3 - New Dosage Form

What TONMYA Treats

1 indications

TONMYA is approved for 1 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Fibromyalgia
Source: FDA Label

TONMYA Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to TONMYA

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

DRIZALMA SPRINKLE
DULOXETINE HYDROCHLORIDE
1 shared
Sun Pharma
Shared indications:
Fibromyalgia
LYRICA
PREGABALIN
1 shared
CP PHARMS
Shared indications:
Fibromyalgia
SAVELLA
MILNACIPRAN HYDROCHLORIDE
1 shared
AbbVie
Shared indications:
Fibromyalgia
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT01151787 CEPH03242010 Ph 3 terminated Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TONMYA FDA Label Details

Indications & Usage

TONMYA is indicated for the treatment of Fibromyalgia.

View full patent landscape →
4 OB patents · 1 families · 86 international docs across 28 countries

TONMYA Patents & Exclusivity

Latest Patent: Mar 2034
Exclusivity: Aug 2028

Patents (4 active)

US10117936 Expires Mar 14, 2034
US10864175 Expires Mar 14, 2034
US9636408 Expires Mar 14, 2034
US9956188 Expires Mar 14, 2034

Exclusivity

NP Until Aug 2028
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for TONMYA

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2034
  • 4 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 3 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.